Robert Zivadinov

List of Publications by Year
in descending order

521 papers	21,507 citations	9786 73 h-index	21540 114 g-index
527 all docs	527 docs citations	527 times ranked	15613 citing authors

#	Article	IF	Citations
1	Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. Journal of the Neurological Sciences, 2005, 231, 29-34.	0.6	446
2	Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2017, 69, 367-377.	2.8	405
3	Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology, 2001, 57, 1239-1247.	1.1	338
4	A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 773-780.	1.9	327
5	Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nature Reviews Neurology, 2011, 7, 332-342.	10.1	320
6	The thalamus and multiple sclerosis. Neurology, 2013, 80, 210-219.	1.1	286
7	Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis. JAMA - Journal of the American Medical Association, 2016, 316, 592.	7.4	284
8	Neocortical Atrophy, Third Ventricular Width, and Cognitive Dysfunction in Multiple Sclerosis. Archives of Neurology, 2006, 63, 1301.	4.5	282
9	Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. Journal of Neurology, 2012, 259, 139-146.	3.6	274
10	The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nature Reviews Neurology, 2016, 12, 714-722.	10.1	274
11	Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology, 2008, 71, 136-144.	1.1	227
12	Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. Journal of Neurology, 2001, 248, 416-421.	3.6	209
13	Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clinical Neuropsychologist, 2010, 24, 1131-1145.	2.3	205
14	Sexual dysfunction in multiple sderosis: a case-control study. 1. Frequency and comparison of groups. Multiple Sclerosis Journal, 1999, 5, 418-427.	3.0	199
15	Three times weekly glatiramer acetate in relapsingâ€“remitting multiple sclerosis. Annals of Neurology, 2013, 73, 705-713.	5.3	194
16	Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology, 2011, 77, 138-144.	1.1	189
17	Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. Journal of Neuroinflammation, 2011, 8, 127.	7.2	186
18	Epidemiology and treatment of multiple sclerosis in elderly populations. Nature Reviews Neurology, 2019, 15, 329-342.	10.1	185

#	Article	IF	Citations
19	Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis. NeuroImage, 2012, 59, 331-339.	4.2	176
20	Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 201-206.	1.9	174
21	Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method. NeuroImage, 2004, 22, 1732-1743.	4.2	172
22	Optical coherence tomography in multiple sclerosis. Lancet Neurology, The, 2006, 5, 853-863.	10.2	165
23	Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1109-1115.	1.9	155
24	Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. Journal of the Neurological Sciences, 2008, 268, 12-17.	0.6	147
25	Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis. Radiology, 2013, 268, 831-841.	7.3	145
26	A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. Journal of NeuroVirology, 2013, 19, 351-358.	2.1	138
27	Extent of cerebellum, subcortical and cortical atrophy in patients with MS. Journal of the Neurological Sciences, 2009, 282, 47-54.	0.6	133
28	Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis. American Journal of Neuroradiology, 2012, 33, 1573-1578.	2.4	133
29	Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain, 2009, 132, 3392-3400.	7.6	130
30	Aging and multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 717-725.	3.0	128
31	Migraine and Tension-Type Headache in Croatia: A Population-Based Survey of Precipitating Factors. Cephalalgia, 2003, 23, 336-343.	3.9	127
32	Exercise Treatment for Postconcussion Syndrome. Journal of Head Trauma Rehabilitation, 2013, 28, 241-249.	1.7	127
33	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Review of Neurotherapeutics, 2016, 16, 777-793.	2.8	126
34	Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Multiple Sclerosis Journal, 1999, 5, 418-427.	3.0	125
35	Sexual dysfunction in multiple sclerosis: a 2-year follow-up study. Journal of the Neurological Sciences, 2001, 187, 1-5.	0.6	117
36	Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology, 2009, 73, 504-510.	1.1	116

#	Article	IF	Citations
37	Interferon Î² for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a032003.	6.2	116
38	Lipid profiles are associated with lesion formation over 24â€…months in interferon-Î² treated patients following the first demyelinating event. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1186-1191.	1.9	114
39	The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. Neural Regeneration Research, 2019, 14, 373.	3.0	114
40	Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: A pilot study. Journal of the Neurological Sciences, 2009, 282, 96-105.	0.6	110
41	Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. Journal of the American College of Cardiology, 2017, 69, 679-691.	2.8	110
42	MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis. Neuroradiology, 2001, 43, 272-278.	2.2	109
43	Clinical-Magnetic Resonance Imaging Correlations in Multiple Sclerosis. , 2005, 15, 10S-21S.		109
44	Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. NeuroImage, 2007, 36, 1294-1300.	4.2	109
45	Risk factors of multiple sclerosis: a case-control study. Neurological Sciences, 2003, 24, 242-247.	1.9	108
46	Rapid disease course in African Americans with multiple sclerosis. Neurology, 2010, 75, 217-223.	1.1	106
47	Gray matter pathology in (chronic) MS: Modern views on an early observation. Journal of the Neurological Sciences, 2009, 282, 12-20.	0.6	105
48	Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy. Acta Neurologica Scandinavica, 2002, 105, 77-82.	2.1	100
49	Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology, 2011, 77, e124-e126.	1.1	99
50	Sexual dysfunction in multiple sderosis: II. Correlation analysis. Multiple Sclerosis Journal, 1999, 5, 428-431.	3.0	96
51	Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-310051.	1.9	95
52	The Use of Standardized Incidence and Prevalence Rates in Epidemiological Studies on Multiple Sclerosis. Neuroepidemiology, 2003, 22, 65-74.	2.3	94
53	Preservation of gray matter volume in multiple sclerosis patients with the MetÂallele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Human Molecular Genetics, 2007, 16, 2659-2668.	2.9	93
54	Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. Multiple Sclerosis Journal, 2017, 23, 1336-1345.	3.0	93

#	Article	IF	Citations
55	Characterizing cognitive function during relapse in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1745-1752.	3.0	92
56	Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 722-730.	3.0	91
57	Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years. American Journal of Neuroradiology, 2013, 34, 1931-1939.	2.4	90
58	Sexual dysfunction in multiple sclerosis: a MRI, neurophysiological and urodynamic study. Journal of the Neurological Sciences, 2003, 210, 73-76.	0.6	89
59	Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients. Multiple Sclerosis Journal, 2016, 22, 1327-1336.	3.0	88
60	Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?. Neurology, 2007, 68, S72-S82.	1.1	87
61	Role of platelets in neuroinflammation: a wide-angle perspective. Journal of Neuroinflammation, 2010, 7, 10.	7.2	86
62	Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. Multiple Sclerosis Journal, 2013, 19, 1478-1484.	3.0	85
63	Thalamic Involvement in Multiple Sclerosis: A Diffusionâ€Weighted Magnetic Resonance Imaging Study. Journal of Neuroimaging, 2003, 13, 307-314.	2.0	84
64	Gray matter atrophy and disability progression in patients with early relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2009, 282, 112-119.	0.6	84
65	Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 189-195.	1.9	84
66	Brain iron accumulation in aging and neurodegenerative disorders. Expert Review of Neurotherapeutics, 2012, 12, 1467-1480.	2.8	83
67	Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis. Archives of Neurology, 2006, 63, 614.	4.5	81
68	Use of MR Venography for Characterization of the Extracranial Venous System in Patients with Multiple Sclerosis and Healthy Control Subjects. Radiology, 2011, 258, 562-570.	7.3	81
69	Olfactory dysfunction and extent of white matter abnormalities in multiple sclerosis: a clinical and MR study. Multiple Sclerosis Journal, 2000, 6, 386-390.	3.0	79
70	Role of MRI in multiple sclerosis I: inflammation and lesions. Frontiers in Bioscience - Landmark, 2004, 9, 665.	3.0	79
71	Validity of the Wisconsin Card Sorting and Delisâ€“Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. Journal of Clinical and Experimental Neuropsychology, 2007, 29, 215-223.	1.3	77
72	Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 965-976.	3.0	77

#	Article	IF	Citations
73	Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report. BMC Medicine, 2011, 9, 22.	5.5	77
74	Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. European Journal of Neurology, 2005, 12, 550-556.	3.3	76
75	The severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis is related to altered cerebrospinal fluid dynamics. Functional Neurology, 2009, 24, 133-8.	1.3	76
76	Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. Radiology, 2018, 289, 487-496.	7.3	75
77	A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. Journal of the Neurological Sciences, 2003, 216, 113-118.	0.6	73
78	Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 407-414.	1.9	73
79	Venous Angioplasty in Patients with Multiple Sclerosis: Results of a Pilot Study. European Journal of Vascular and Endovascular Surgery, 2012, 43, 116-122.	1.5	73
80	Regional lobar atrophy predicts memory impairment in multiple sclerosis. American Journal of Neuroradiology, 2005, 26, 1824-31.	2.4	73
81	Olfactory loss in multiple sclerosis. Journal of the Neurological Sciences, 1999, 168, 127-130.	0.6	72
82	Depressive symptoms and MRI changes in multiple sclerosis. European Journal of Neurology, 2002, 9, 491-496.	3.3	72
83	I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Multiple Sclerosis Journal, 2007, 13, 490-501.	3.0	72
84	Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5â€year longitudinal study. European Journal of Neurology, 2019, 26, 87.	3.3	72
85	Role of MRI in multiple sclerosis II: brain and spinal cord atrophy. Frontiers in Bioscience - Landmark, 2004, 9, 647.	3.0	70
86	A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Multiple Sclerosis Journal, 2016, 22, 1709-1718.	3.0	69
87	Central Nervous System Atrophy and Clinical Status in Multiple Sclerosis. Journal of Neuroimaging, 2004, 14, 27S.	2.0	68
88	Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study. PLoS ONE, 2013, 8, e53996.	2.5	68
89	Jugular Venous Reflux and White Matter Abnormalities in Alzheimer's Disease: A Pilot Study. Journal of Alzheimer's Disease, 2014, 39, 601-609.	2.6	67
90	The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. Journal of Neurology, 2008, 255, 61-74.	3.6	66

#	Article	IF	Citations
91	Potential involvement of the extracranial venous system in central nervous system disorders and aging. BMC Medicine, 2013, 11, 260.	5.5	66
92	Serum neurofilament light chain levels associations with gray matter pathology: a 5â€year longitudinal study. Annals of Clinical and Translational Neurology, 2019, 6, 1757-1770.	3.7	66
93	Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 514-521.	1.9	66
94	Use of neck magnetic resonance venography, Doppler sonography and selective venography for diagnosis of chronic cerebrospinal venous insufficiency: a pilot study in multiple sclerosis patients and healthy controls. International Angiology, 2010, 29, 127-39.	0.9	66
95	White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. NeuroImage, 2009, 47, 2083-2089.	4.2	65
96	Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS. NeuroImage, 2006, 29, 505-514.	4.2	63
97	Value of MR Venography for Detection of Internal Jugular Vein Anomalies in Multiple Sclerosis: A Pilot Longitudinal Study. American Journal of Neuroradiology, 2011, 32, 938-946.	2.4	63
98	Recent Developments in Imaging of Multiple Sclerosis. Neurologist, 2011, 17, 185-204.	0.7	63
99	Subcortical Atrophy Is Associated with Cognitive Impairment in Mild Parkinson Disease: A Combined Investigation of Volumetric Changes, Cortical Thickness, and Vertex-Based Shape Analysis. American Journal of Neuroradiology, 2014, 35, 2257-2264.	2.4	63
100	Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study. Radiology, 2016, 281, 884-895.	7.3	63
101	Neuroimaging In Multiple Sclerosis. International Review of Neurobiology, 2007, 79, 449-474.	2.0	62
102	Comparison of Three Different Methods for Measurement of Cervical Cord Atrophy in Multiple Sclerosis. American Journal of Neuroradiology, 2008, 29, 319-325.	2.4	62
103	Gender-related differences in MS: a study of conventional and nonconventional MRI measures. Multiple Sclerosis Journal, 2009, 15, 345-354.	3.0	62
104	Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Multiple Sclerosis Journal, 1999, 5, 428-431.	3.0	62
105	Gray matter correlations of cognition in incident Parkinson's disease. Movement Disorders, 2010, 25, 629-633.	3.9	61
106	Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. Multiple Sclerosis Journal, 2020, 26, 1670-1681.	3.0	61
107	HLAâ€ÐRB1*1501, â€ÐQB1*0301, â€ÐQB1*0302, â€ÐQB1*0602, and â€ÐQB1*0603 Alleles are Associated With More Severe Disease Outcome on Mri in Patients With Multiple Sclerosis. International Review of Neurobiology, 2007, 79, 521-535.	2.0	60
108	Iron deposition in multiple sclerosis lesions measured by susceptibilityâ€weighted imaging filtered phase: A case control study. Journal of Magnetic Resonance Imaging, 2012, 36, 73-83.	3.4	60

#	Article	IF	Citations
109	Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality. NeuroImage, 2018, 167, 438-452.	4.2	60
110	Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 620-625.	1.9	58
111	Increased tissue damage and lesion volumes in African Americans with multiple sclerosis. Neurology, 2010, 74, 538-544.	1.1	58
112	Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. NeuroImage: Clinical, 2018, 17, 444-451.	2.7	58
113	Predicting neuropsychological abnormalities in multiple sclerosis. Journal of the Neurological Sciences, 2006, 245, 67-72.	0.6	57
114	Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. Journal of Neuroimmunology, 2007, 188, 167-174.	2.3	57
115	Recommendations for Multimodal Noninvasive and Invasive Screening for Detection of Extracranial Venous Abnormalities Indicative of Chronic Cerebrospinal Venous Insufficiency: A Position Statement of the International Society for Neurovascular Disease. Journal of Vascular and Interventional Radiology, 2014, 25, 1785-1794.e17.	0.5	57
116	Modeling Axonal Degeneration Within the Anterior Visual System. Archives of Neurology, 2008, 65, 26-35.	4.5	56
117	Cerebrospinal fluid amyloid-Â and phenotypic heterogeneity in de novo Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 537-543.	1.9	56
118	Conventional and Advanced Imaging in Neuromyelitis Optica. American Journal of Neuroradiology, 2014, 35, 1458-1466.	2.4	56
119	Neuropsychological Impairment in Systemic Lupus Erythematosus: A Comparison with Multiple Sclerosis. Neuropsychology Review, 2008, 18, 149-166.	4.9	55
120	Iron Deposition on SWI-Filtered Phase in the Subcortical Deep Gray Matter of Patients with Clinically Isolated Syndrome May Precede Structure-Specific Atrophy. American Journal of Neuroradiology, 2012, 33, 1596-1601.	2.4	55
121	Neurofilament levels are associated with bloodâ€“brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 220-231.	3.0	55
122	Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study. International Angiology, 2010, 29, 158-75.	0.9	54
123	Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 36-42.	3.0	53
124	Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 515-527.	2.9	53
125	Corticosteroids for Multiple Sclerosis: I. Application for Treating Exacerbations. Neurotherapeutics, 2007, 4, 618-626.	4.4	52
126	Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease. Movement Disorders, 2019, 34, 1006-1013.	3.9	51

#	Article	IF	Citations
127	Brain atrophy and white matter hyperintensities in early Parkinson's disease. Movement Disorders, 2009, 24, 2233-2241.	3.9	50
128	Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. BMC Neurology, 2011, 11, 128.	1.8	50
129	Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. Movement Disorders, 2011, 26, 297-301.	3.9	50
130	Prevalence of Radiologically Isolated Syndrome and White Matter Signal Abnormalities in Healthy Relatives of Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2014, 35, 106-112.	2.4	50
131	Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis. Journal of Neuroimaging, 2018, 28, 490-495.	2.0	50
132	Positivity of cytomegalovirus antibodies predicts a better clinical and radiological outcome in multiple sclerosis patients. Neurological Research, 2006, 28, 262-269.	1.3	48
133	Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model. NeuroImage, 2014, 90, 207-217.	4.2	48
134	Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. NeuroImage: Clinical, 2017, 15, 769-779.	2.7	48
135	Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives. Expert Review of Neurotherapeutics, 2011, 11, 1277-1294.	2.8	47
136	Substantia Nigra Free Water Increases Longitudinally in Parkinson Disease. American Journal of Neuroradiology, 2018, 39, 479-484.	2.4	47
137	Prevalence of Migraine in Croatia: A Population-Based Survey. Headache, 2001, 41, 805-812.	3.9	46
138	Cine cerebrospinal fluid imaging in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2012, 36, 825-834.	3.4	46
139	Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. Multiple Sclerosis Journal, 2015, 21, 858-865.	3.0	46
140	Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. NeuroImage, 2007, 36, 746-754.	4.2	45
141	Assessing Abnormal Iron Content in the Deep Gray Matter of Patients with Multiple Sclerosis versus Healthy Controls. American Journal of Neuroradiology, 2012, 33, 252-258.	2.4	45
142	Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. Journal of Neurology, 2014, 261, 1735-1744.	3.6	45
143	Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. Journal of Lipid Research, 2015, 56, 2010-2018.	4.2	45
144	Cortical atrophy and personality in multiple sclerosis.. Neuropsychology, 2008, 22, 432-441.	1.3	44

#	Article	IF	Citations
145	Multimodal imaging in systemic lupus erythematosus patients with diffuse neuropsychiatric involvement. Lupus, 2013, 22, 675-683.	1.6	44
146	Subcortical Deep Gray Matter Pathology in Patients with Multiple Sclerosis Is Associated with White Matter Lesion Burden and Atrophy but Not with Cortical Atrophy: A Diffusion Tensor MRI Study. American Journal of Neuroradiology, 2014, 35, 912-919.	2.4	44
147	Bilingual Aphasia and Subcortical-Cortical Lesions. Perceptual and Motor Skills, 2001, 92, 803-814.	1.3	43
148	Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. Journal of Neuroimmunology, 2007, 187, 159-165.	2.3	43
149	Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity. Multiple Sclerosis Journal, 2008, 14, 759-763.	3.0	43
150	Prospective randomized trial of venous angioplasty in MS (PREMiSe). Neurology, 2014, 83, 441-449.	1.1	43
151	Serum lipid profile changes predict neurodegeneration in interferon-Î²1a-treated multiple sclerosis patients. Journal of Lipid Research, 2017, 58, 403-411.	4.2	43
152	Cognitive Profiles of Aging in Multiple Sclerosis. Frontiers in Aging Neuroscience, 2019, 11, 105.	3.4	43
153	Phytosterols ameliorate clinical manifestations and inflammation in experimental autoimmune encephalomyelitis. Inflammation Research, 2011, 60, 457-465.	4.0	42
154	MRI in the evaluation of pediatric multiple sclerosis. Neurology, 2016, 87, S88-96.	1.1	42
155	Odor identification deficit in mild cognitive impairment and Alzheimer's disease is associated with hippocampal and deep gray matter atrophy. Psychiatry Research - Neuroimaging, 2016, 255, 87-93.	1.8	42
156	Differential effects of aging on motor and cognitive functioning in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1385-1393.	3.0	42
157	Short-term brain atrophy changes in relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2004, 223, 185-193.	0.6	41
158	Dynamics of interferon-Î² modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-Î² neutralizing antibodies. Journal of Neuroimmunology, 2006, 176, 125-133.	2.3	41
159	Pharmacological Treatment of Early Multiple Sclerosis. Drugs, 2008, 68, 73-83.	10.9	41
160	Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. Neurodegenerative Disease Management, 2019, 9, 149-172.	2.2	41
161	Central Nervous System Atrophy and Clinical Status in Multiple Sclerosis. , 2004, 14, 27-35.		41
162	HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. Journal of Neurology, 2003, 250, 1099-1106.	3.6	40

#	Article	IF	Citations
163	Risk Factors for Chronic Cerebrospinal Venous Insufficiency (CCSVI) in a Large Cohort of Volunteers. PLoS ONE, 2011, 6, e28062.	2.5	40
164	Intra- and Extraluminal Structural and Functional Venous Anomalies in Multiple Sclerosis, as Evidenced by 2 Noninvasive Imaging Techniques. American Journal of Neuroradiology, 2012, 33, 16-23.	2.4	40
165	Inflammation induces neuro-lymphatic protein expression in multiple sclerosis brain neurovasculature. Journal of Neuroinflammation, 2013, 10, 125.	7.2	40
166	Correlation of sexual dysfunction and brain magnetic resonance imaging in multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 108-110.	3.0	39
167	Steroids and brain atrophy in multiple sclerosis. Journal of the Neurological Sciences, 2005, 233, 73-81.	0.6	39
168	MRI correlates of disability progression in patients with CIS over 48Âmonths. NeuroImage: Clinical, 2014, 6, 312-319.	2.7	39
169	Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e190.	6.0	39
170	Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?. Multiple Sclerosis Journal, 2017, 23, 242-252.	3.0	39
171	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 51-61.	3.0	39
172	A randomized evaluation of the TriGuardâ„¢ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. European Heart Journal, 2021, 42, 2670-2679.	2.2	39
173	Pharmacogenetics of MXA SNPs in interferon-Î² treated multiple sclerosis patients. Journal of Neuroimmunology, 2007, 182, 236-239.	2.3	38
174	Interferon-Î² treatment for relapsing multiple sclerosis. Expert Opinion on Biological Therapy, 2008, 8, 1435-1447.	3.1	38
175	Information processing speed, neural efficiency, and working memory performance in multiple sclerosis: Differential relationships with structural magnetic resonance imaging. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 1129-1145.	1.3	38
176	White Matter Hyperintensities and Mild Cognitive Impairment in Parkinson's Disease. Journal of Neuroimaging, 2015, 25, 754-760.	2.0	38
177	Interdependence of oxysterols with cholesterol profiles in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 792-801.	3.0	38
178	Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 642-647.	2.4	38
179	Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. European Heart Journal, 2018, 39, 1687-1697.	2.2	38
180	Coagulation Pathways in Neurological Diseases: Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 409.	2.4	38

#	Article	IF	Citations
181	Recovery of cognitive function after relapse in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 71-78.	3.0	38
182	Thalamic Involvement in Multiple Sclerosis: A Diffusion-Weighted Magnetic Resonance Imaging Study. , 2003, 13, 307-314.		38
183	MMP-9 microsatellite polymorphism and multiple sclerosis. Journal of Neuroimmunology, 2004, 152, 147-153.	2.3	37
184	Antiphospholipid antibodies: Paradigm in transition. Journal of Neuroinflammation, 2009, 6, 3.	7.2	37
185	Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?. Expert Review of Neurotherapeutics, 2016, 16, 765-775.	2.8	37
186	Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. Multiple Sclerosis Journal, 2016, 22, 770-781.	3.0	37
187	Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis. Human Brain Mapping, 2019, 40, 5231-5241.	3.6	37
188	Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. Vaccines, 2020, 8, 50.	4.4	37
189	Frontal parenchymal atrophy measures in multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 562-568.	3.0	36
190	Therapeutic Considerations for Disease Progression in Multiple Sclerosis. Archives of Neurology, 2005, 62, 1519-30.	4.5	36
191	Multiple sclerosis and cerebral endothelial dysfunction: Mechanisms. Pathophysiology, 2011, 18, 3-12.	2.2	36
192	Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNÎ²-1a in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1125-1134.	3.0	36
193	Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1075-1081.	1.9	36
194	An improved FSL-FIRST pipeline for subcortical gray matter segmentation to study abnormal brain anatomy using quantitative susceptibility mapping (QSM). Magnetic Resonance Imaging, 2017, 39, 110-122.	1.8	36
195	Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. Radiology, 2019, 293, 424-433.	7.3	36
196	Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study. Journal of Neurology, 2019, 266, 866-875.	3.6	36
197	Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Multiple Sclerosis Journal, 2008, 14, 1061-1067.	3.0	35
198	Geneâ€“environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. Journal of Neuroimmunology, 2009, 209, 123-130.	2.3	35

#	Article	IF	Citations
199	Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 859-864.	1.9	35
200	Quantifying errors in flow measurement using phase contrast magnetic resonance imaging: comparison of several boundary detection methods. Magnetic Resonance Imaging, 2015, 33, 185-193.	1.8	34
201	Diffusion Tensor Imaging Alterations in Patients With Postconcussion Syndrome Undergoing Exercise Treatment. Journal of Head Trauma Rehabilitation, 2015, 30, E32-E42.	1.7	34
202	Brain responses to altered auditory feedback during musical keyboard production: An fMRI study. Brain Research, 2014, 1556, 28-37.	2.2	33
203	Cognitive and White Matter Tract Differences in MS and Diffuse Neuropsychiatric Systemic Lupus Erythematosus. American Journal of Neuroradiology, 2015, 36, 1874-1883.	2.4	33
204	Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition. Multiple Sclerosis Journal, 2019, 25, 1243-1254.	3.0	33
205	Aging and Brain Atrophy in Multiple Sclerosis. Journal of Neuroimaging, 2019, 29, 527-535.	2.0	33
206	Iron and Volume in the Deep Gray Matter: Association with Cognitive Impairment in Multiple Sclerosis. American Journal of Neuroradiology, 2015, 36, 57-62.	2.4	32
207	Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain. NeuroImage: Clinical, 2018, 18, 1007-1016.	2.7	32
208	Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals. NeuroImage: Clinical, 2018, 17, 530-540.	2.7	32
209	Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 541-553.	3.0	32
210	Changes of Cine Cerebrospinal Fluid Dynamics in Patients with Multiple Sclerosis Treated with Percutaneous Transluminal Angioplasty: A Case-control Study. Journal of Vascular and Interventional Radiology, 2013, 24, 829-838.	0.5	31
211	Jugular venous reflux and brain parenchyma volumes in elderly patients with mild cognitive impairment and Alzheimerâ€™s disease. BMC Neurology, 2013, 13, 157.	1.8	31
212	Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow. Journal of Magnetic Resonance Imaging, 2014, 40, 1215-1222.	3.4	31
213	Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsingâ€“remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study. Multiple Sclerosis Journal, 2017, 23, 818-829.	3.0	31
214	Complementary and Alternative Medicine Usage by Multiple Sclerosis Patients: Results from a Prospective Clinical Study. Journal of Alternative and Complementary Medicine, 2018, 24, 596-602.	2.1	31
215	Assessing â€˜No Evidence of Disease Activityâ€™ Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study. CNS Drugs, 2018, 32, 75-84.	5.9	31
216	Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study. Journal of Lipid Research, 2019, 60, 1190-1198.	4.2	31

#	Article	IF	Citations
217	The role of noninvasive and invasive diagnostic imaging techniques for detection of extra-cranial venous system anomalies and developmental variants. BMC Medicine, 2013, 11, 155.	5.5	30
218	Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. Neurology, 2019, 93, e611-e623.	1.1	30
219	Reliability and validity of neuropsychological screening and assessment strategies in MS. Journal of Neurology, 2007, 254, II22-II25.	3.6	29
220	A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2010, 3, 15-28.	3.5	29
221	Alemtuzumab and multiple sclerosis: therapeutic application. Expert Opinion on Biological Therapy, 2010, 10, 421-429.	3.1	29
222	Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. Journal of the Neurological Sciences, 2011, 311, 86-91.	0.6	29
223	Patterns of dietary and herbal supplement use by multiple sclerosis patients. Journal of Neurology, 2012, 259, 637-644.	3.6	29
224	Effect of Age on MRI Phase Behavior in the Subcortical Deep Gray Matter of Healthy Individuals. American Journal of Neuroradiology, 2013, 34, 2144-2151.	2.4	29
225	Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature. Clinical Rheumatology, 2014, 33, 1829-1833.	2.2	29
226	Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2008, 267, 28-35.	0.6	28
227	Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 567-576.	3.0	28
228	Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. Expert Opinion on Biological Therapy, 2017, 17, 1163-1172.	3.1	28
229	Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study. Multiple Sclerosis Journal, 2020, 26, 322-332.	3.0	28
230	Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. Journal of Neuroimmunology, 2012, 243, 61-68.	2.3	27
231	Simultaneous Determination of Oxysterols, Cholesterol and 25-Hydroxy-Vitamin D3 in Human Plasma by LC-UV-MS. PLoS ONE, 2015, 10, e0123771.	2.5	27
232	Thalamus volume and ambulation in multiple sclerosis: a cross-sectional study. Neurodegenerative Disease Management, 2016, 6, 23-29.	2.2	27
233	Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis. American Journal of Neuroradiology, 2016, 37, 1010-1016.	2.4	27
234	Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium. Multiple Sclerosis Journal, 2020, 26, 99-108.	3.0	27

#	Article	IF	Citations
235	Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron <scp>MRI</scp>. Human Brain Mapping, 2021, 42, 1463-1474.	3.6	27
236	Reproducibility and Accuracy of Quantitative Magnetic Resonance Imaging Techniques of Whole-Brain Atrophy Measurement in Multiple Sclerosis. Journal of Neuroimaging, 2005, 15, 27-36.	2.0	26
237	Signal abnormalities on 1.5 and 3ÂTesla brain MRI in multiple sclerosis patients and healthy controls. A morphological and spatial quantitative comparison study. NeuroImage, 2009, 47, 1352-1362.	4.2	26
238	MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. Journal of Neurology, 2010, 257, 63-71.	3.6	26
239	Iron deposition and inflammation in multiple sclerosis. Which one comes first?. BMC Neuroscience, 2011, 12, 60.	1.9	26
240	Establishing pathological cut-offs for lateral ventricular volume expansion rates. NeuroImage: Clinical, 2018, 18, 494-501.	2.7	26
241	Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage. Journal of the Neurological Sciences, 2018, 393, 128-134.	0.6	26
242	Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of followâ€up. European Journal of Neurology, 2020, 27, 188.	3.3	26
243	Is Gadolinium Enhancement Predictive of the Development of Brain Atrophy in Multiple Sclerosis? A Review of the Literature. Journal of Neuroimaging, 2002, 12, 302-309.	2.0	25
244	Detection of Cortical Lesions is Dependent on Choice of Slice Thickness in Patients with Multiple Sclerosis. International Review of Neurobiology, 2007, 79, 475-489.	2.0	25
245	3D FLAIRED: 3D fluid attenuated inversion recovery for enhanced detection of lesions in multiple sclerosis. Magnetic Resonance in Medicine, 2012, 68, 874-881.	3.0	25
246	Comparison of Intravascular Ultrasound with Conventional Venography for Detection of Extracranial Venous Abnormalities Indicative of Chronic Cerebrospinal Venous Insufficiency. Journal of Vascular and Interventional Radiology, 2013, 24, 1487-1498.e1.	0.5	25
247	Early magnetic resonance imaging predictors of clinical progression after 48Âmonths in clinically isolated syndrome patients treated with intramuscular interferon Î²â€1a. European Journal of Neurology, 2015, 22, 1113-1123.	3.3	25
248	White Matter Tract Injury is Associated with Deep Gray Matter Iron Deposition in Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 107-113.	2.0	25
249	Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 123-130.	2.4	25
250	Multimodal Imaging of Retired Professional Contact Sport Athletes Does Not Provide Evidence of Structural and Functional Brain Damage. Journal of Head Trauma Rehabilitation, 2018, 33, E24-E32.	1.7	25
251	Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine. American Journal of Neuroradiology, 2018, 39, 2237-2242.	2.4	25
252	Hemostasis biomarkers in multiple sclerosis. European Journal of Neurology, 2018, 25, 1169-1176.	3.3	25

#	Article	IF	Citations
253	Vascular aspects of multiple sclerosis: emphasis on perfusion and cardiovascular comorbidities. Expert Review of Neurotherapeutics, 2019, 19, 445-458.	2.8	25
254	Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls. NeuroImage, 2019, 186, 308-320.	4.2	25
255	A Magnetization Transfer MRI Study of Deep Gray Matter Involvement in Multiple Sclerosis. Journal of Neuroimaging, 2006, 16, 302-310.	2.0	24
256	Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. Pathophysiology, 2011, 18, 53-60.	2.2	24
257	Arterial, venous and other vascular risk factors in multiple sclerosis. Neurological Research, 2012, 34, 754-760.	1.3	24
258	Advances in understanding gray matter pathology in multiple sclerosis: Are we ready to redefine disease pathogenesis?. BMC Neurology, 2012, 12, 9.	1.8	24
259	Influence of Personality on the Relationship Between Gray Matter Volume and Neuropsychiatric Symptoms in Multiple Sclerosis. Psychosomatic Medicine, 2013, 75, 253-261.	2.0	24
260	Gray matter SWI-filtered phase and atrophy are linked to disability in MS. Frontiers in Bioscience - Elite, 2013, E5, 525-532.	1.8	24
261	Longitudinal personality change associated with cognitive decline in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1909-1912.	3.0	24
262	Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS. American Journal of Neuroradiology, 2018, 39, 289-295.	2.4	24
263	Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study. Multiple Sclerosis and Related Disorders, 2019, 34, 103-111.	2.0	24
264	Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients. Multiple Sclerosis Journal, 2020, 26, 201-209.	3.0	24
265	Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	24
266	Sensitivity and specificity for screening of chronic cerebrospinal venous insufficiency using a multimodal non-invasive imaging approach in patients with multiple sclerosis. Functional Neurology, 2011, 26, 205-14.	1.3	24
267	CSF dynamics and brain volume in multiple sclerosis are associated with extracranial venous flow anomalies: a pilot study. International Angiology, 2010, 29, 140-8.	0.9	24
268	The rs2030324 SNP of brain-derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis. Pathophysiology, 2011, 18, 43-52.	2.2	23
269	Improved assessment of multiple sclerosis lesion segmentation agreement via detection and outline error estimates. BMC Medical Imaging, 2012, 12, 17.	2.7	23
270	White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. Human Brain Mapping, 2018, 39, 3682-3690.	3.6	23

#	Article	IF	Citations
271	Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology. Multiple Sclerosis Journal, 2022, 28, 1101-1111.	3.0	23
272	Use of perfusion- and diffusion-weighted imaging in differential diagnosis of acute and chronic ischemic stroke and multiple sclerosis. Neurological Research, 2008, 30, 816-826.	1.3	22
273	Active Cognitive Reserve Influences the Regional Atrophy to Cognition Link in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2013, 19, 1128-1133.	1.8	22
274	Retinal nerve fiber layer thickness and thalamus pathology in multiple sclerosis patients. European Journal of Neurology, 2014, 21, 1137.	3.3	22
275	Blood circulating microparticle species in relapsingâ€“remitting and secondary progressive multiple sclerosis. A caseâ€“control, cross sectional study with conventional MRI and advanced iron content imaging outcomes. Journal of the Neurological Sciences, 2015, 355, 84-89.	0.6	22
276	Long-Term Neurocognitive, Psychosocial, and Magnetic Resonance Imaging Outcomes in Pediatric-Onset Acute Disseminated Encephalomyelitis. Pediatric Neurology, 2016, 57, 64-73.	2.1	22
277	Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 36, 101388.	2.0	22
278	Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study. American Journal of Neuroradiology, 2019, 40, 620-625.	2.4	22
279	Serum neurofilament light chain and optical coherence tomography measures in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	22
280	Normalized regional brain atrophy measurements in multiple sclerosis. Neuroradiology, 2003, 45, 793-798.	2.2	21
281	Evidence for gray matter pathology in multiple sclerosis: A neuroimaging approach. Journal of the Neurological Sciences, 2009, 282, 1-4.	0.6	21
282	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. Journal of Neuroimmunology, 2014, 273, 58-64.	2.3	21
283	An Exploratory Study of Mild Cognitive Impairment of Retired Professional Contact Sport Athletes. Journal of Head Trauma Rehabilitation, 2018, 33, E16-E23.	1.7	21
284	A Preliminary Study of Early-Onset Dementia of Former Professional Football and Hockey Players. Journal of Head Trauma Rehabilitation, 2018, 33, E1-E8.	1.7	21
285	Characterization of leptomeningeal inflammation in rodent experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis. Experimental Neurology, 2019, 314, 82-90.	4.1	21
286	Functional Connectivity and Structural Disruption in the Defaultâ€Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis. Journal of Neuroimaging, 2020, 30, 523-530.	2.0	21
287	Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study. , 2003, 13, 307-14.		21
288	Retinal architecture predicts pupillary reflex metrics in MS. Multiple Sclerosis Journal, 2009, 15, 479-486.	3.0	20

#	Article	IF	Citations
289	Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. Journal of the Neurological Sciences, 2014, 338, 128-134.	0.6	20
290	Internal Jugular Vein Cross-Sectional Area Enlargement Is Associated with Aging in Healthy Individuals. PLoS ONE, 2016, 11, e0149532.	2.5	20
291	A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Longâ€Term Comparative Study. Journal of Neuroimaging, 2017, 27, 620-629.	2.0	20
292	Neurocognition and Cerebral Lesion Burden in High-Risk Patients Before Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 384-392.	2.9	20
293	Cholesterol affects retinal nerve fiber layer thickness in patients with multiple sclerosis with optic neuritis. European Journal of Neurology, 2013, 20, 1264-1271.	3.3	19
294	Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense â€œblack holesâ€• a post hoc magnetic resonance imaging analysis. Journal of Neurology, 2015, 262, 648-653.	3.6	19
295	Thalamic white matter in multiple sclerosis: A combined diffusionâ€tensor imaging and quantitative susceptibility mapping study. Human Brain Mapping, 2018, 39, 4007-4017.	3.6	19
296	Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Crossâ€Sectional Structural <scp>MRI</scp> Study. Journal of Magnetic Resonance Imaging, 2021, 53, 731-739.	3.4	19
297	A sensitive, noise-resistant method for identifying focal demyelination and remyelination in patients with multiple sclerosis via voxel-wise changes in magnetization transfer ratio. Journal of the Neurological Sciences, 2009, 282, 86-95.	0.6	18
298	Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years. European Journal of Neurology, 2016, 23, 1101-1109.	3.3	18
299	Dirtyâ€Appearing White Matter in the Brain is Associated with Altered Cerebrospinal Fluid Pulsatility and Hypertension in Individuals without Neurologic Disease. Journal of Neuroimaging, 2016, 26, 136-143.	2.0	18
300	Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2016, 22, 920-927.	1.8	18
301	Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses. Multiple Sclerosis Journal, 2021, 27, 1077-1087.	3.0	18
302	Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?. Journal of Neurology, 2021, 268, 2578-2588.	3.6	18
303	Incidence and Prevalence of Myasthenia gravis in the County of the Coast and Gorski kotar, Croatia, 1976 through 1996¹. Neuroepidemiology, 1998, 17, 265-272.	2.3	17
304	Interferon Inhibitory Activity in Patients With Multiple Sclerosis. Archives of Neurology, 2006, 63, 1579.	4.5	17
305	Is there a link between the extracranial venous system and central nervous system pathology?. BMC Medicine, 2013, 11, 259.	5.5	17
306	Jugular venous reflux and plasma endothelin-1 are associated with cough syncope: a case control pilot study. BMC Neurology, 2013, 13, 9.	1.8	17

#	Article	IF	Citations
307	Preliminary investigation of cognitive function in aged multiple sclerosis patients: Challenges in detecting comorbid Alzheimerâ€™s disease. Multiple Sclerosis and Related Disorders, 2018, 22, 52-56.	2.0	17
308	Quantitative susceptibility mapping (QSM) with an extended physical model for MRI frequency contrast in the brain: a proofâ€ofâ€concept of quantitative susceptibility and residual (QUASAR) mapping. NMR in Biomedicine, 2018, 31, e3999.	2.8	17
309	High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: AÂfatigue-metabolism nexus?. Journal of Clinical Lipidology, 2019, 13, 654-663.e1.	1.5	17
310	Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. Journal of Clinical Medicine, 2019, 8, 344.	2.4	17
311	Teriflunomide's Effect on Glia in Experimental Demyelinating Disease: A Neuroimaging and Histologic Study. Journal of Neuroimaging, 2019, 29, 52-61.	2.0	17
312	MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2020, 20, 821-834.	2.8	17
313	Staging and stratifying cognitive dysfunction in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 463-471.	3.0	17
314	Effect of Treatment with Interferon Beta-1a on Changes in Voxel-Wise Magnetization Transfer Ratio in Normal Appearing Brain Tissue and Lesions of Patients with Relapsingâ€“Remitting Multiple Sclerosis: A 24-Week, Controlled Pilot Study. PLoS ONE, 2014, 9, e91098.	2.5	17
315	Heart disease, overweight, and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities. Neurological Research, 2012, 34, 819-827.	1.3	16
316	Blood Pressure Management and Evolution of Thrombolysis-associated Intracerebral Hemorrhage in Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2012, 21, 852-859.	1.6	16
317	Increased contrast enhancing lesion activity in relapsingâ€“remitting multiple sclerosis migraine patients. NeuroImage: Clinical, 2015, 9, 110-116.	2.7	16
318	Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?. Multiple Sclerosis Journal, 2018, 24, 205-213.	3.0	16
319	Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures. Multiple Sclerosis and Related Disorders, 2019, 27, 298-304.	2.0	16
320	Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opinion on Drug Safety, 2020, 19, 1121-1142.	2.4	16
321	The Role of Quantitative Neuroimaging Indices in the Differentiation of Ischemia From Demyelination: An Analytical Study With Case Presentation. International Review of Neurobiology, 2007, 79, 491-519.	2.0	15
322	No Association Between Conventional Brain MR Imaging and Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis. American Journal of Neuroradiology, 2012, 33, 1913-1917.	2.4	15
323	Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis. BMC Neurology, 2012, 12, 26.	1.8	15
324	Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: Results of the PREMiSe pilot study. BMC Neurology, 2013, 13, 151.	1.8	15

#	Article	IF	Citations
325	Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 937-943.	1.9	15
326	Methods for the computation of templates from quantitative magnetic susceptibility maps (QSM): Toward improved atlasâ€•and voxelâ€based analyses (VBA). Journal of Magnetic Resonance Imaging, 2017, 46, 1474-1484.	3.4	15
327	Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures. Journal of the Neurological Sciences, 2018, 388, 175-181.	0.6	15
328	A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS. American Journal of Neuroradiology, 2019, 40, 446-452.	2.4	15
329	Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102389.	2.0	15
330	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
331	Internal Jugular Vein Cross-Sectional Area and Cerebrospinal Fluid Pulsatility in the Aqueduct of Sylvius: A Comparative Study between Healthy Subjects and Multiple Sclerosis Patients. PLoS ONE, 2016, 11, e0153960.	2.5	15
332	Chronic cerebrospinal venous insufficiency in multiple sclerosis: a historical perspective. Functional Neurology, 2011, 26, 181-95.	1.3	15
333	Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. Neurological Research, 2012, 34, 761-769.	1.3	14
334	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. Journal of Neuroimmunology, 2013, 263, 121-127.	2.3	14
335	Tract-based spatial statistics analysis of diffusion-tensor imaging data in pediatric- and adult-onset multiple sclerosis. Human Brain Mapping, 2014, 35, 53-60.	3.6	14
336	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 424-433.	2.5	14
337	Use of natalizumab in multiple sclerosis: current perspectives. Expert Opinion on Biological Therapy, 2016, 16, 1151-1162.	3.1	14
338	An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practiceâ€”The MSâ€MRIUS Study. Journal of Neuroimaging, 2017, 27, 339-347.	2.0	14
339	Atrophied brain lesion volume, a magnetic resonance imaging biomarker for monitoring neurodegenerative changes in multiple sclerosis. Quantitative Imaging in Medicine and Surgery, 2018, 8, 979-983.	2.0	14
340	The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsingâ€“Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. CNS Drugs, 2018, 32, 763-770.	5.9	14
341	Five-Year Longitudinal Study of Neck Vessel Cross-Sectional Area in Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 1703-1709.	2.4	14
342	Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study. Journal of Comparative Effectiveness Research, 2019, 8, 305-316.	1.4	14

#	Article	IF	Citations
343	Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinsonâ€™s disease, mild cognitive impairment, Alzheimerâ€™s disease, and elderly healthy controls. Neurobiology of Aging, 2020, 90, 84-92.	3.1	14
344	Chronic Cerebrospinal Vascular Insufficiency Is Not Associated with HLA DRB1*1501 Status in Multiple Sclerosis Patients. PLoS ONE, 2011, 6, e16802.	2.5	14
345	CMV Infection Attenuates the Disease Course in a Murine Model of Multiple Sclerosis. PLoS ONE, 2012, 7, e32767.	2.5	14
346	Regional Specificity of Magnetization Transfer Imaging in Multiple Sclerosis. Journal of Neuroimaging, 2008, 18, 130-136.	2.0	13
347	Application of hidden Markov random field approach for quantification of perfusion/diffusion mismatch in acute ischemic stroke. Neurological Research, 2008, 30, 827-834.	1.3	13
348	Immunologic and MRI markers of the therapeutic effect of IFN-Î²-1a in relapsing-remitting MS. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e176.	6.0	13
349	Effects of diet on brain iron levels among healthy individuals: an MRI pilot study. Neurobiology of Aging, 2015, 36, 1678-1685.	3.1	13
350	Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome. American Journal of Neuroradiology, 2015, 36, 1457-1464.	2.4	13
351	Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study. American Journal of Neuroradiology, 2018, 39, 1480-1486.	2.4	13
352	Plasma levels of soluble NCAM in multiple sclerosis. Journal of the Neurological Sciences, 2019, 396, 36-41.	0.6	13
353	Late onset multiple sclerosis is associated with more severe ventricle expansion. Multiple Sclerosis and Related Disorders, 2020, 46, 102588.	2.0	13
354	Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 47, 102653.	2.0	13
355	Acute demyelinating optic neuritis: a review. Frontiers in Bioscience - Landmark, 2008, 13, 2376.	3.0	13
356	HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. Journal of Neuroimmunology, 2011, 236, 76-80.	2.3	12
357	Development of gray matter atrophy in relapsingâ€“remitting multiple sclerosis is not gender dependent: Results of a 5-year follow-up study. Clinical Neurology and Neurosurgery, 2013, 115, S42-S48.	1.4	12
358	Neurosarcoidosis. American Journal of Therapeutics, 2013, 20, 292-299.	0.9	12
359	Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. BMC Neurology, 2015, 15, 232.	1.8	12
360	Brain atrophy measurements should be used to guide therapy monitoring in MS â€“ YES. Multiple Sclerosis Journal, 2016, 22, 1522-1524.	3.0	12

#	Article	IF	Citations
361	Olfactory identification deficit predicts white matter tract impairment in Alzheimer's disease. Psychiatry Research - Neuroimaging, 2017, 266, 90-95.	1.8	12
362	Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis. PLoS ONE, 2017, 12, e0182729.	2.5	12
363	Jugular Venous Flow Quantification Using Doppler Sonography. Ultrasound in Medicine and Biology, 2018, 44, 1762-1769.	1.5	12
364	Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MSâ€MRIUS. Journal of Neuroimaging, 2018, 28, 399-405.	2.0	12
365	Reinforcer pathology: Common neural substrates for delay discounting and snack purchasing in prediabetics. Brain and Cognition, 2019, 132, 80-88.	1.8	12
366	Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 245-252.	3.0	12
367	Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients. Frontiers in Neurology, 2020, 11, 700.	2.4	12
368	Sexâ€Specific Differences in Life Span Brain Volumes in Multiple Sclerosis. Journal of Neuroimaging, 2020, 30, 342-350.	2.0	12
369	Reproducibility and Accuracy of Quantitative Magnetic Resonance Imaging Techniques of Whole-Brain Atrophy Measurement in Multiple Sclerosis. , 2005, 15, 27-36.		12
370	Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A caseâ€“control diffusion imaging study. Pathophysiology, 2011, 18, 61-68.	2.2	11
371	Regionally Distinct White Matter Lesions Do Not Contribute to Regional Gray Matter Atrophy in Patients with Multiple Sclerosis. , 2011, 21, 210-218.		11
372	Phase White Matter Signal Abnormalities in Patients with Clinically Isolated Syndrome and Other Neurologic Disorders. American Journal of Neuroradiology, 2014, 35, 1916-1923.	2.4	11
373	MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy. BMC Neurology, 2014, 14, 131.	1.8	11
374	Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC). BMC Neurology, 2016, 16, 102.	1.8	11
375	Stable neuropsychiatric status in multiple sclerosis: a 3-year study. Multiple Sclerosis Journal, 2016, 22, 569-574.	3.0	11
376	Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study. European Journal of Neurology, 2018, 25, 584-e36.	3.3	11
377	Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2018, 25, 37-42.	2.0	11
378	A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. Journal of Neurology, 2020, 267, 802-811.	3.6	11

#	Article	IF	Citations
379	Conscientiousness and deterioration in employment status in multiple sclerosis over 3â€‰years. Multiple Sclerosis Journal, 2021, 27, 1125-1135.	3.0	11
380	Considering patient age when treating multiple sclerosis across the adult lifespan. Expert Review of Neurotherapeutics, 2021, 21, 353-364.	2.8	11
381	Vascular pathology of multiple sclerosis. Neurological Research, 2012, 34, 735-737.	1.3	10
382	Magnetization transfer imaging of acute black holes in patients on glatiramer acetate. Frontiers in Bioscience - Elite, 2012, E4, 1496-1504.	1.8	10
383	MRI characteristics of familial and sporadic multiple sclerosis patients. Multiple Sclerosis Journal, 2013, 19, 1145-1152.	3.0	10
384	Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders. CNS Drugs, 2019, 33, 1073-1086.	5.9	10
385	Tagged cine magnetic resonance imaging to quantify regional mechanical changes after acute myocardial infarction. Magnetic Resonance Imaging, 2020, 66, 208-218.	1.8	10
386	Diagnosis of depression in multiple sclerosis is predicted by frontalâ€“parietal white matter tract disruption. Journal of Neurology, 2021, 268, 169-177.	3.6	10
387	Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis. Journal of the Neurological Sciences, 2021, 427, 117552.	0.6	10
388	DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis. NeuroImage: Clinical, 2021, 30, 102652.	2.7	10
389	Time for Change â€“ Evolution of Real-world Evidence Outcome Measures in Multiple Sclerosis Exemplified by Fingolimod. European Neurological Review, 2015, 9, 136.	0.5	10
390	Marijuana Use by Patients with Multiple Sclerosis. International Journal of MS Care, 2019, 21, 57-62.	1.0	10
391	Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease. Movement Disorders, 2022, 37, 490-501.	3.9	10
392	Update on the relationships between neuropsychological dysfunction and structural MRI in multiple sclerosis. Expert Review of Neurotherapeutics, 2006, 6, 323-331.	2.8	9
393	Is functional MRI feasible for multiâ€center studies on multiple sclerosis?. European Journal of Neurology, 2008, 15, 109-110.	3.3	9
394	Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. Multiple Sclerosis International, 2013, 2013, 1-8.	0.8	9
395	Internal jugular vein narrowing and body mass index in healthy individuals and multiple sclerosis patients. Veins and Lymphatics, 2014, 3, .	0.1	9
396	Reserve-building activities in multiple sclerosis patients and healthy controls: a descriptive study. BMC Neurology, 2015, 15, 135.	1.8	9

#	Article	IF	Citations
397	Transcatheter aortic valve replacement: perioperative stroke and beyond. Expert Review of Neurotherapeutics, 2017, 17, 327-334.	2.8	9
398	Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis. European Journal of Neurology, 2020, 27, 235-243.	3.3	9
399	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2001-2013.	3.0	9
400	Functional network dynamics and decreased conscientiousness in multiple sclerosis. Journal of Neurology, 2022, 269, 2696-2706.	3.6	9
401	Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age. Multiple Sclerosis and Related Disorders, 2022, 57, 103406.	2.0	9
402	Effect of MRI coregistration on serial short-term brain volume changes in multiple sclerosis. Neurological Research, 2006, 28, 275-279.	1.3	8
403	Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis. Neurological Research, 2012, 34, 793-801.	1.3	8
404	Role of Venoplasty for Treatment of Multiple Sclerosis: Value of Open-label Studies and Surrogate Treatment Outcomes. Journal of Vascular and Interventional Radiology, 2012, 23, 1308-1310.	0.5	8
405	Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. Journal of the Neurological Sciences, 2014, 347, 229-234.	0.6	8
406	Extracranial venous angioplasty is ineffective to treat MS. Nature Reviews Neurology, 2018, 14, 129-130.	10.1	8
407	Extracranial Veins in Multiple Sclerosis: Is There a Role for Vascular Surgery?. European Journal of Vascular and Endovascular Surgery, 2018, 56, 618-621.	1.5	8
408	Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis. Journal of Neuroimaging, 2019, 29, 615-623.	2.0	8
409	Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1433-1436.	3.0	8
410	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. Journal of Clinical Lipidology, 2020, 14, 675-684.e2.	1.5	8
411	Detection of Monocyte/Macrophage and Microglia Activation in the TMEV Model of Chronic Demyelination Using USPIOâ€Enhanced Ultrahighâ€Field Imaging. Journal of Neuroimaging, 2020, 30, 769-778.	2.0	8
412	Subcutaneous anti-CD20 antibody treatment delays gray matter atrophy in human myelin oligodendrocyte glycoprotein-induced EAE mice. Experimental Neurology, 2021, 335, 113488.	4.1	8
413	Advanced magnetic resonance imaging metrics: Implications for multiple sclerosis clinical trials. Methods and Findings in Experimental and Clinical Pharmacology, 2009, 31, 29.	0.8	8
414	Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis. PLoS ONE, 2015, 10, e0129503.	2.5	8

#	Article	IF	Citations
415	CSF neurofilament light chain predicts 10-year clinical and radiologic worsening in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110603.	1.0	8
416	Progressive Cerebral Disease in Lymphomatoid Granulomatosis Causes Anterograde Amnesia and Neuropsychiatric Disorder. Journal of Neuroimaging, 2006, 16, 163-166.	2.0	7
417	Funding CCSVI research is/was a waste of valuable time, money and intellectual energy: No. Multiple Sclerosis Journal, 2013, 19, 858-860.	3.0	7
418	Age-related brain atrophy may be mitigated by internal jugular vein enlargement in male individuals without neurologic disease. Phlebology, 2017, 32, 125-134.	1.2	7
419	Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis. Current Neurovascular Research, 2017, 14, 266-273.	1.1	7
420	Effect of switching from glatiramer acetate 20â€¯mg/daily to glatiramer acetate 40â€¯mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study. Journal of the Neurological Sciences, 2018, 387, 152-156.	0.6	7
421	Lipoprotein(a) Levels Are Associated with the Size of Extracranial Arteries in Multiple Sclerosis. Journal of Vascular Research, 2020, 57, 16-23.	1.4	7
422	Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642097075.	3.5	7
423	Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy. Fluids and Barriers of the CNS, 2020, 17, 9.	5.0	7
424	beta2-microglobulin serum level is not a marker of disease activity in multiple sclerosis. European Journal of Neurology, 2004, 11, 455-460.	3.3	6
425	New MRI criteria in the diagnosis of multiple sclerosis. Lancet Neurology, The, 2007, 6, 664-665.	10.2	6
426	The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsingâ€Remitting Multiple Sclerosis. Journal of Neuroimaging, 2015, 25, 989-995.	2.0	6
427	Reserve-related activities and MRI metrics in multiple sclerosis patients and healthy controls: an observational study. BMC Neurology, 2016, 16, 108.	1.8	6
428	No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study. Current Medical Research and Opinion, 2018, 34, 1431-1440.	1.9	6
429	Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?. Clinical Autonomic Research, 2019, 29, 329-338.	2.5	6
430	Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke?. Thrombosis and Haemostasis, 2019, 119, 175-178.	3.4	6
431	Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Multiple Sclerosis and Related Disorders, 2019, 27, 65-73.	2.0	6
432	Interpretation of Brain Volume Increase in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 401-407.	2.0	6

#	Article	IF	Citations
433	Neck Vessel Crossâ€Sectional Area Measured with MRI: Scanâ€Rescan Reproducibility for Longitudinal Evaluations. Journal of Neuroimaging, 2018, 28, 48-56.	2.0	6
434	Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study. Current Neurovascular Research, 2019, 16, 215-223.	1.1	6
435	Advanced magnetic resonance imaging metrics: Implications for multiple sclerosis clinical trials. Methods and Findings in Experimental and Clinical Pharmacology, 2009, 31, 29.	0.8	6
436	Corticosteroids for Multiple Sclerosis: II. Application for Disease-Modifying Effects. Neurotherapeutics, 2007, 4, 627-632.	4.4	5
437	Pathophysiology of demyelinating disorders. Pathophysiology, 2011, 18, 1-2.	2.2	5
438	Magnetization transfer imaging of acute black holes in patients on glatiramer acetate. Frontiers in Bioscience - Elite, 2012, E4, 1496.	1.8	5
439	Chronic cerebrospinal venous insufficiency is not associated with cognitive impairment in multiple sclerosis. BMC Medicine, 2013, 11, 167.	5.5	5
440	A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsingâ€“remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2015, 8, 59-70.	3.5	5
441	No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5â€‰years. BMC Neurology, 2019, 19, 121.	1.8	5
442	High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis. Journal of the Neurological Sciences, 2020, 418, 117120.	0.6	5
443	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. NeuroImage: Clinical, 2021, 32, 102802.	2.7	5
444	Brain atrophy and clinical characteristics predicting SDMT performance in multiple sclerosis: A 10-year follow-up study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732199239.	1.0	5
445	Fatigue and Mood States in Nursing Home and Nonambulatory Home-Based Patients with Multiple Sclerosis. International Journal of MS Care, 2017, 19, 297-302.	1.0	5
446	Chapter 4 Neuroimaging of Cognitive Impairments in Vascular Disease. International Review of Neurobiology, 2009, 84, 49-80.	2.0	4
447	Improved operator agreement and efficiency using the minimum area contour change method for delineation of hyperintense multiple sclerosis lesions on FLAIR MRI. BMC Medical Imaging, 2013, 13, 29.	2.7	4
448	Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurology, 2013, 13, 173.	1.8	4
449	Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease. Therapeutic Advances in Neurological Disorders, 2016, 9, 105-117.	3.5	4
450	The Role of Highâ€Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis. Journal of Neuroimaging, 2018, 28, 328-337.	2.0	4

#	Article	IF	Citations
451	Neurolymphatic biomarkers of brain endothelial inflammatory activation: Implications for multiple sclerosis diagnosis. Life Sciences, 2019, 229, 116-123.	4.3	4
452	Relationships Among Circulating Levels of Hemostasis Inhibitors, Chemokines, Adhesion Molecules, and MRI Characteristics in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 553616.	2.4	4
453	Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 1577-1583.	2.4	4
454	Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis. Diagnostics, 2020, 10, 685.	2.6	4
455	Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives. Neurodegenerative Disease Management, 2021, 11, 329-340.	2.2	4
456	Olfactory dysfunction and extent of white matter abnormalities in multiple sclerosis: a clinical and MR study. Multiple Sclerosis Journal, 2000, 6, 386-390.	3.0	4
457	BILINGUAL APHASIA AND SUBCORTICAL-CORTICAL LESIONS. Perceptual and Motor Skills, 2001, 92, 803.	1.3	4
458	Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis. Journal of Neurology, 0, , .	3.6	4
459	Role of Magnetic Resonance Imaging in the Diagnosis and Prognosis of Multiple Sclerosis. , 2005, , 55-89.		3
460	Comment on â€œno evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onsetâ€• Annals of Neurology, 2011, 69, 1062-1063.	5.3	3
461	Regarding CCSVI and MS: A Never-ending Story or a New Chapter?. European Journal of Vascular and Endovascular Surgery, 2012, 43, 129-130.	1.5	3
462	Impact of tissue atrophy on high-pass filtered MRI signal phase-based assessment in large-scale group-comparison studies: a simulation study. Frontiers in Physics, 2013, 1, .	2.1	3
463	No Regional Gray Matter Atrophy Differences between Pediatricâ€•and Adultâ€Onset Relapsingâ€Remitting Multiple Sclerosis. Journal of Neuroimaging, 2014, 24, 63-67.	2.0	3
464	Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsingâ€“remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly. Journal of Neuroimmunology, 2015, 281, 44-50.	2.3	3
465	Susceptibility Weighted MRI in Rodents at 9.4 T. Methods in Molecular Biology, 2018, 1718, 205-234.	0.9	3
466	Longitudinal Magnetic Resonance Imaging of Cerebral Microbleeds in Multiple Sclerosis Patients. Diagnostics, 2020, 10, 942.	2.6	3
467	Tonsillectomy in multiple sclerosis patients: Retrospective, case-controlled, exploratory study. Multiple Sclerosis and Related Disorders, 2020, 42, 102131.	2.0	3
468	Cervical Spinal Cord Lesions and Atrophy versus Brain Measures in Explaining Physical Disability in Multiple Sclerosis. Radiology, 2020, 296, 616-618.	7.3	3

#	Article	IF	Citations
469	Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes. NeuroImage: Clinical, 2021, 29, 102554.	2.7	3
470	Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI. NeuroImage: Clinical, 2021, 31, 102705.	2.7	3
471	Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis. Journal of Neurology, 2021, 268, 4796-4808.	3.6	3
472	The cholesterol autoxidation products, 7-ketocholesterol and 7Î²-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102864.	2.0	3
473	Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis. Journal of Neuroimaging, 2021, 31, 995-1002.	2.0	3
474	Differential Diagnosis of Cognitive Decline in Elderly Individuals With Multiple Sclerosis. Cognitive and Behavioral Neurology, 2020, 33, 294-300.	0.9	3
475	Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS. Drugs of Today, 2008, 44, 601.	1.1	3
476	Magnetic Resonance Imaging and Analysis in Multiple Sclerosis. Current Clinical Neurology, 2020, , 109-136.	0.2	3
477	Patient-Reported Outcome Severity and Emotional Salience Network Disruption in Multiple Sclerosis. Brain Imaging and Behavior, 2022, 16, 1252-1259.	2.1	3
478	Time course of lesion-induced atrophy in multiple sclerosis. Journal of Neurology, 2022, 269, 4478-4487.	3.6	3
479	Chronic cerebrospinal venous insufficiency: Have we found the cause and cure of MS?. Neurology, 2011, 77, 1710-1712.	1.1	2
480	Retinal nerve fiber thickness and MRI white matter abnormalities in healthy relatives of multiple sclerosis patients. Clinical Neurology and Neurosurgery, 2013, 115, S49-S54.	1.4	2
481	Global and regional brain atrophy is associated with low or retrograde facial vein flow in multiple sclerosis. Veins and Lymphatics, 2017, 6, .	0.1	2
482	TCT-43 First-in-human experience of a novel transradial device for embolic deflection during transcatheter aortic valve replacement. Journal of the American College of Cardiology, 2018, 72, B19.	2.8	2
483	Why Is Cognitive Impairment Present in Multiple Sclerosis? Insights from Functional MRI. Radiology, 2018, 288, 552-553.	7.3	2
484	Use of patient-reported data in determining factors contributing to internal jugular vein stenosis outcomes. Annals of Translational Medicine, 2020, 8, 421-421.	1.7	2
485	Brain atrophy and employment in multiple sclerosis patients: a 10-year follow-up study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732090248.	1.0	2
486	Imaging of extracranial obstructive venous disease. Italian Journal of Vascular and Endovascular Surgery, 2018, 25, .	1.0	2

#	Article	IF	Citations
487	Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110615.	1.0	2
488	Comparison of a 1.5T standard vs. 3T optimized protocols in multiple sclerosis patients. Minerva Medica, 2012, 103, 97-102.	0.9	2
489	Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset. Journal of Neuroimaging, 2022, 32, 910-919.	2.0	2
490	What you see is what you get: Coupling function with structure in the visual system. Neurology, 2007, 69, 2119-2120.	1.1	1
491	Endovascular Treatment for Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis: A Longitudinal, Magnetic Resonance Imaging, Blinded Pilot Study. Journal of Vascular Surgery, 2010, 51, 794.	1.1	1
492	Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study. International Journal of Molecular Sciences, 2012, 13, 5659-5673.	4.1	1
493	Unclear Value of Positional MR Angiography in Evaluating Cerebral Venous Outflow Hemodynamics. American Journal of Neuroradiology, 2012, 33, E30-E30.	2.4	1
494	Olfactory Identification Deficit as a Predictor of White Matter Tract Integrity in Alzheimer's Disease. American Journal of Geriatric Psychiatry, 2015, 23, S103-S104.	1.2	1
495	Shedding Risk with Intracerebral Inoculation of Theilerâ€™s Murine Encephalomyelitis Virus. Applied Biosafety, 2016, 21, 142-150.	0.5	1
496	103â€…Exploring the influence of quantitative magnetic resonance imaging on decision-making in multiple sclerosis clinical practice. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A41.1-A41.	1.9	1
497	Network Dynamics and Cognitive Impairment in Multiple Sclerosis: Functional MRIâ€“based Decoupling of Complex Relationships. Radiology, 2019, 292, 458-459.	7.3	1
498	Measuring Aqueduct of Sylvius Cerebrospinal Fluid Flow in Multiple Sclerosis Using Different Software. Diagnostics, 2021, 11, 325.	2.6	1
499	Neuroimaging of Multiple Sclerosis. , 2011, , 81-105.		1
500	Editorial: Update on Vascular Contributions to Age-Related Neurodegenerative Diseases and Cognitive Impairment - Research of ISNVD 2020 Meeting. Frontiers in Neurology, 2021, 12, 797486.	2.4	1
501	MRIâ€based thalamic volumetry in multiple sclerosis using FSLâ€FIRST: Systematic assessment of common error modes. Journal of Neuroimaging, 2022, 32, 245-252.	2.0	1
502	Apolipoprotein E Îµ4-positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: a 15-year disease history model based on a 4-year longitudinal study. Folia Biologica, 2010, 56, 242-51.	0.6	1
503	Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis. European Radiology, 2022, , 1.	4.5	1
504	Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients. European Journal of Neurology, 2022, , .	3.3	1

#	Article	IF	Citations
505	Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103906.	2.0	1
506	Incidence and prevalence of motor neuron disease in Coastal and Mountainous Regions, Croatia, 1984â€“1993. A preliminary survey. European Journal of Neurology, 1997, 4, 376-381.	3.3	0
507	Title is missing!. Journal of the Neurological Sciences, 2005, 231, 103-104.	0.6	0
508	Transcranial sonography of deep gray nuclei. Neurology, 2009, 73, 1006-1007.	1.1	0
509	Regarding CCSVI: Is Blinding the Key?. European Journal of Vascular and Endovascular Surgery, 2012, 43, 126.	1.5	0
510	The Role of Diagnostic Imaging Techniques for Detection of Extracranial Venous System Abnormalities Associated with Central Nervous System Disorders. , 2014, , 1-30.		0
511	Development Of An Innovative Observational Study To Assess Multiple Sclerosis Disease Progression In Real World Clinical Practice. Value in Health, 2016, 19, A104-A105.	0.3	0
512	Role of Neuroimaging in Multiple Sclerosis. , 2016, , 443-478.		0
513	The Role of Diagnostic Imaging Techniques for Detection of Extracranial Venous System Abnormalities Associated with Central Nervous System Disorders. , 2016, , 953-979.		0
514	TCT-422 Pre-procedural white matter lesion burden predicts MRI outcomes in transcatheter aortic valve replacement (TAVR): The Sentinel Trial. Journal of the American College of Cardiology, 2017, 70, B173-B174.	2.8	0
515	TCT-425 Impact of cerebral protection in aortic stenosis patients treated with transcatheter aortic valve replacement on functional and structural integrity of the brain: results of a combined patient-level analysis of three randomized controlled trials. Journal of the American College of Cardiology, 2017, 70, B174-B175.	2.8	0
516	Reply. JACC: Cardiovascular Interventions, 2018, 11, 1420.	2.9	0
517	Decrease in size of secondary neck vessels and cerebral aqueduct enlargement in multiple sclerosis: a 5-year longitudinal MRI study. Veins and Lymphatics, 2019, 8, .	0.1	0
518	Role of Imaging Techniques in Discerning Neurobehavioral Changes in Ischemic, Neurodegenerative and Demyelinating Disorders. , 2009, , 17-54.		0
519	Phytosterols (PS) as immunomodulators of Multiple Sclerosis (MS). FASEB Journal, 2010, 24, 332.8.	0.5	0
520	Advances in Magnetic Resonance Imaging of Multiple Sclerosis. , 2011, , 111-129.		0
521	Editorial of Special Issue â€œMultiple Sclerosis: From Diagnostic Biomarkers to Imaging and Clinical Predictorsâ€• Diagnostics, 2022, 12, 482.	2.6	0